Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review article

Viral respiratory infections and psychosis: A review of the literature and the implications of COVID-19

Stephanie S. Kulaga *, Christopher W.T. Miller

University of Maryland School of Medicine, 701 W. Pratt St., 4th Floor, Baltimore, MD 21201, United States

ARTICLE INFO

Keywords:
Coronavirus
COVID-19
Inflammation
Influenza
Maternal infection
Neurodevelopment
Pregnancy
Psychosis
SARS-CoV-2
Schizophrenia
Viral infections

ABSTRACT

The historical association between respiratory infections and neuropsychiatric symptoms dates back centuries, with more recent literature highlighting a link between viral infections and schizophrenia. Maternal influenza infection during pregnancy has been associated with the development of schizophrenia in offspring. Viral infections in neonates, children, and adolescents have also been associated with later development of schizophrenia. Neuroinvasive and/or systemic infections are thought to increase risk for psychopathology via inflammatory mechanisms, particularly when exposure occurs during critical neurodevelopmental windows. Several human coronaviruses (HCoVs) have been associated with psychotic disorders and increasing reports of the neuropsychiatric manifestations of COVID-19 suggest it has neuroinvasive properties similar to those of other HCoVs. These properties, in conjunction with its ability to generate a massive inflammatory response, suggest that COVID-19 may also contribute to future psychopathology. This review will summarize the psychopathogenic mechanisms of viral infections and discuss the neuroinvasive and inflammatory properties of COVID-19 that could contribute to the development of psychotic disorders, with a focus on in utero, neonatal, and childhood exposure.

1. Introduction

Infectious theories of mental illness were introduced in the 19th century and have been frequently revisited (Yolken and Torrey, 1995). Observations of neuropsychiatric symptoms in respiratory illness date back even further, to the 1385 German flu pandemic (Menninger, 1919). Literature from subsequent pandemics characterize the flu not as a respiratory illness, but a multisystem disease with inherent neuropsychiatric effects including depression, insomnia, and psychosis (Honigsbaum, 2013). Psychotic symptoms reported in this earlier literature were largely self-limited and most famously described in Karl Menninger’s 1919 case series on psychosis following the Spanish flu, noting that most psychotic symptoms had resolved by the five-year follow-up (Menninger, 1919, 1926). It was not until the 1990s that epidemiological observations revealing a correlation between late winter/early spring births and adult schizophrenia generated greater interest in the notion that viral respiratory infections could be a risk factor for persistent mental illness, specifically schizophrenia (Yolken and Torrey, 1995). Since then, several extensively reviewed birth cohort studies have linked maternal influenza infection during pregnancy to development of schizophrenia in offspring (Boksa, 2008; Brown, 2006; Kępińska et al., 2020; Selten and Termorshuizen, 2017). Childhood and peripubertal infections have also been characterized as risk factors for adult-onset psychosis (Dalman et al., 2008; Hickie and Banati, 2009; Khandaker et al., 2012). The relevance of these findings is of mounting importance, particularly as a number of immunologic disturbances have been described in adults with schizophrenia (Howes, 2017; Müller, 2018).

Now, over a century after the Spanish flu, we face an equally alarming threat in the COVID-19 pandemic. Though primarily thought of as a respiratory virus, it too has been shown to damage multiple organ systems, including the nervous system (Wu et al., 2020). Rising reports of neuropsychiatric manifestations of COVID-19 have surfaced, including delirium (Beach et al., 2020), encephalitis (Li et al., 2020d), strokes (Morassi et al., 2020), and smell and taste abnormalities (Machado and Gutierrez, 2020). Others have already drawn attention to the possibility of long-term neuropsychiatric sequelae from COVID-19 (Cowan, 2020; Taquet et al., 2021; Troyer et al., 2020), including psychosis, which was linked to different forms of coronaviruses in one retrospective study (Severance et al., 2011). This review will expand on...
the link between viral respiratory illness and psychosis, with a discussion of the inflammatory model of schizophrenia, psychopathogenic mechanisms of viral infections, and COVID-19 literature suggestive of psychiatric sequelae. Given the evidence that risk for future psychopathology is mediated by timing of exposure (Ratnayake et al., 2013), we will focus on the impact of individual infection during neurodevelopmentally vulnerable periods and of maternal infection on neonates.

2. Inflammatory model of schizophrenia

Genetic predisposition, psychosocial stress, and biological insults are all thought to play a synergistic role in the pathophysiology of schizophrenia (Walker and Diforio, 1997). Stress during both pre- and postnatal neurodevelopment is particularly impactful and primes individuals for a pathological response to a second “hit,” typically during adolescence or early adulthood (Maynard et al., 2001). For example, exposure to prenatal maternal infection followed by psychological trauma in adolescence has been associated with a higher risk of developing schizophrenia than either insult alone (Debost et al., 2017). Both psychosocial and biological stressors, the latter including infection and immune activation, cause hypothalamic-pituitary-adrenal (HPA) axis dysregulation, which has been linked to abnormalities observed in schizophrenia. These include elevated baseline cortisol, reduced hippocampal volume, and disturbances in dopamine and glutamate transmission (Popoli et al., 2012; Puressner, 2017). Immune activation also has more direct implications in schizophrenia, illustrated by shared genetic risk factors with autoimmune disease (Pouget et al., 2019), presence of inflammatory biomarkers, and evidence of central nervous system (CNS) inflammation in response to both local and systemic infection (Müller, 2018). Microglia, the brain’s innate immune cells, release inflammatory cytokines in response to stress or infection and, like the HPA axis, can be primed by early stressors to have an exaggerated response to later insults. Microglial overactivation is also implicated in schizophrenia and may result in aberrant synaptic pruning and altered neurotransmitter metabolism secondary to excess cytokine release (Howes, 2017; Raison et al., 2017). Fig. 1 is a pictorial representation of how constitutional (e.g., biological and genetic) and environmental factors intersect in promoting an inflammatory substrate for the development of psychotic illness.

3. Viral infections and schizophrenia

Viruses damage the CNS via both direct invasion and immune activation. This can lead to acute neuropsychiatric effects from processes such as encephalitis and meningitis (Somand and Meurer, 2009), with the potential for long-term psychopathology.

Fig. 1. Inflammatory model of psychotic illness. Perinatal factors (constitutional and environmental) may prime the individual to be sensitized (1st hit) to the effects of future stressors (2nd hit), which may inform long-lasting changes predisposing to psychopathology. Relevant changes include maintenance of stress response impacting neurodevelopment (e.g., reduced hippocampal volume), alterations in circulating neurotransmitter levels (e.g., dopamine and glutamate), and heightened immune activation, with overexpression of cytokines and a sustained inflammatory substrate that may lead to aberrant neuronal pruning and cell death. The combination of these factors underlies a possible inflammatory basis for development of psychotic illness. Key: DA = dopamine, GLU = glutamate, HPA = hypothalamic-pituitary-adrenal, IL = interleukin, TNF = tumor necrosis factor.
3.1. Viral neuroinvasion

Viruses have developed several tactics to access the CNS. They infect leukocytes that carry them across the blood-brain barrier (BBB), hijack retrograde axonal transport machinery from peripheral nerves, bind CNS endothelial proteins to gain entry, and invade the olfactory nerve (McGavern and Kang, 2011). Neurotropic viruses linked to schizophrenia include influenza, herpesviruses, enteroviruses, and retroviruses, among others (Fatemi, 2009). In patients with schizophrenia, antigens from such viruses have been found in post-mortem brain tissue (Stevens et al., 1983) and antibody titers against them have been shown to be higher than in healthy controls (Krause et al., 2010). There is also evidence that viruses alter dopamine metabolism (Jang et al., 2009; Li et al., 2006) and affect glutamate transmission via molecular mimicry at N-methyl-D-aspartate (NMDA) receptors (Kannan et al., 2017; Kemptinska et al., 2020), leading to changes that may inform psychotic symptoms.

3.2. Immune activation

The sheer number of viruses implicated in schizophrenia indicates that the causative link is likely not pathogen-specific, but immune-mediated (Müller, 2010). Because CNS infection is so threatening to an organism, the local immune response tends to be robust. Local CNS response is also triggered by systemic infection, which causes microglial activation and cytokine release in the brain (Raison et al., 2017). Proinflammatory cytokines are elevated in both the blood and cerebrospinal fluid (CSF) of patients with schizophrenia, with serum interleukin (IL) 6 notably linked to both presence and severity of disease (Müller, 2018, 2010). Complement, which plays a role in synaptic pruning, has also been found to be elevated in first-episode psychosis patients with poor treatment response (Druart and Le Magueresse, 2019; Mondelli et al., 2020).

3.3. Critical periods

Effects on the CNS appear to be greatest when infections occur in critical neurodevelopmental windows such as childhood and adolescence (Blomstrom et al., 2014; Hickie and Banati, 2009). A large meta-analysis showed a nearly two-fold increased risk of adult non-affective psychosis associated with childhood CNS infection, particularly viral infection (Khandaker et al., 2012). Cohort studies of children hospitalized for any type of infection showed highest risk of later psychosis in those infected under age three or in preadolescence (Blomstrom et al., 2014; Liang and Chikritzhs, 2012). Elevated childhood IL-6 correlates with later psychosis risk in a dose-dependent manner (Khandaker et al., 2014) and both childhood and adolescent elevations in the inflammatory marker C-reactive protein (CRP) are associated with adult schizophrenia (Metcalf et al., 2017; Müller, 2018).

4. Maternal infection and schizophrenia

Fetal brain development begins during the third week of gestation, with the most rapid period of myelination occurring in the first two postnatal years (Cordeiro et al., 2015). Thus, maternal infection, inflammation, and stress during the prenatal and neonatal periods carry the greatest risk for the fetus/infant. Importantly, maternal infection is the most robustly supported infectious risk factor for schizophrenia (Kemptinska et al., 2020). Some viruses have the potential to directly infect the fetus in utero. The TORCH pathogens (Toxoplasmosis, Other, Rubella, Cytomegalovirus, and Herpes), for example, are linked to schizophrenia and implicated in fetal brain anomalies and neurodevelopmental disorders (Al-Haddad et al., 2019; Brown et al., 2005; Brown, 2006; Pugliesz et al., 2017). Influenza, on the other hand, has only rarely been reported to cross the placenta (Brown et al., 2004; Lieberman et al., 2011; Yawn et al., 1971), yet there is a large body of literature associating maternal influenza with schizophrenia in offspring (Kemptinska et al., 2020). The association of maternal respiratory infection and schizophrenia in offspring has been demonstrated primarily in the first two trimesters, with some conflicting evidence as to whether first- or second-trimester infection confers greater risk (Brown et al., 2004, 2000; Mednick, 1988).

4.1. Maternal immune activation

As with childhood and later infection, the role that maternal infection plays in the risk of offspring developing schizophrenia is thought to be more related to inflammation than to any one pathogen (Brown, 2006). Elevation in inflammatory cytokines following infection in pregnancy is termed maternal immune activation (Boulanger-Bertolus et al., 2018). Many of these cytokines are implicated in neurodevelopmental regulation (Fatemi, 2009), and indeed maternal immune activation has been associated with abnormalities in dopaminergic and GABAergic neurons, microglia, and Schwann cells in offspring (Kemptinska et al., 2020). Increased levels of maternal IL-8 and CRP in humans are related to development of schizophrenia in offspring (Brown et al., 2004; Canetta et al., 2014). Maternal fever, which supports immune response, may play a role as well. Hyperthermia poses greatest risk to the CNS in early development (Edwards, 2007) when high temperatures can disrupt neuronal migration (Hinoue et al., 2001). The placenta, which serves to transfer oxygen, nutrients, and other needed substances from mother to fetus, can also transport inflammatory mediators and pathogenic antibodies generated during infection (al-Haddad et al., 2019; Donnelly and Campling, 2019; Kemptinska et al., 2020).

5. Human coronaviruses and nervous system involvement

Since its identification in December 2019, the SARS-CoV-2 virus responsible for COVID-19 has infected over 130 million people worldwide (World Health Organization, 2021). It is the newest member of the human coronavirus (HCoV) group, identified in the 1960s (Mahase, 2020). The most common HCoVs infections present as simple colds (Kahn, 2006), but prior to COVID-19 there were two HCoVs that caused outbreaks of severe respiratory disease. Severe Acute Respiratory Syndrome (SARS) infected about 8000 people from 2002 to 2004 and Middle East Respiratory Syndrome (MERS) infected roughly 2500 people between 2012 and 2018 (National Institute of Allergy and Infectious Diseases, 2020). COVID-19 has greatly surpassed these outbreaks in both incidence and infectivity, bringing unprecedented attention to HCoVs. Increasing attention has been paid to its neuropsychiatric complications, which can range from mild to severe, and include headaches and dizziness (Mao et al., 2020; Zhu et al., 2020), delirium (Beach et al., 2020), meningitis, encephalitis (Li et al., 2020d; Steardo et al., 2020), seizures (Mao et al., 2020), and strokes (Morassi et al., 2020). A substantial portion of those affected have reported fatigue, impaired cognition, anxiety, and depression, with symptoms often persisting for months beyond initial infection (Graham et al., 2021; Huang et al., 2021a; Mazza et al., 2021; Taquet et al., 2021). These reports have understandably alarmed both the medical community and public. As described with influenza, HCoVs can significantly impact the nervous system.

5.1. Neuropsychiatric complications of HCoVs

Although SARS and MERS were known as respiratory infections, both had the ability to infect the nervous system (Li et al., 2016; Netland et al., 2008). Complications included peripheral neuropathies (Tsai et al., 2004), encephalopathies, motor deficits, paralysis, and coma (Arabi et al., 2015; Wu et al., 2020). Psychiatric manifestations included depression, anxiety, mania, and psychosis, though the former two were thought to be related to the stress of having a life-threatening and stigmatizing illness, while the latter two were nearly always associated with steroid use (Cheng et al., 2004; Rogers et al., 2020). The most
compelling data linking HCoVs to psychosis are from Severance et al. (2011), who found that individuals with psychotic symptoms and a diagnosed mood or psychotic disorder had significantly higher seropositivity rates for the endemic HCoVs. Given that these HCoVs typically produce mild illness and that inflammation is the unifying link between viral infections and psychosis, it is suspected that COVID-19, a more severe infection capable of inducing a massive inflammatory response (Steardo et al., 2020), is even more likely to contribute to future psychotic symptoms. Though it is unclear if there are data linking SARS to later-onset or chronic psychosis, those most at risk for this outcome (i.e., neonates and children) would have only recently entered the period of late adolescence or early adulthood, when psychotic disorders often emerge. In the next section we will outline the neuroinvasive and inflammatory features of COVID-19 most relevant to the pathogenesis of schizophrenia and discuss their impact in the populations most likely to be affected.

6. Neuroinvasion and inflammation in COVID-19

SARS-CoV-2 is thought to have similar neurotropism to SARS-CoV and likely enters the CNS via the hematogenous route (Baig, 2020) or via peripheral neurons, using retrograde axonal transport to reach the brain (Wu et al., 2020). The two share 79% genomic homogeneity (Kolifarhood et al., 2020) and the same cell entry receptor, angiotensin-converting enzyme 2 (ACE2). ACE2 is expressed in both neurons and glia (Steardo et al., 2020) and has a ten- to twenty-fold higher binding affinity for SARS-CoV-2 than SARS-CoV (Wrapp et al., 2020).

6.1. Role of ACE2

While overall ACE2 expression in the CNS is low (Li et al., 2020c), there are several areas of relatively higher expression. These include dopaminergic and serotonergic nuclei, glutamatergic neurons, and the lateral ventricles. In the substantia nigra, the percent expression of ACE2 approaches that of the lungs (Chen et al., 2021). These areas are neurochemically and structurally implicated in schizophrenia (DeLisi et al., 2006; Stepnicki et al., 2018; Walker et al., 2018), and while damage to them is not necessarily causative, their relative vulnerability to infection could play a role in shaping future psychopathology. ACE2 also shares significant genetic co-expression with dopamine decarboxylase, an enzyme involved in dopamine and serotonin synthesis. SARS-CoV was seen to downregulate ACE2, and it has been suggested that the ability of SARS-CoV-2 to do the same could result in altered neurotransmitter levels (Nataf, 2020; Verdecchia, 2020).

6.2. Demyelination

Increasing numbers of case reports and series describe COVID-19 patients with associated demyelinating disease (Maury et al., 2021). Both peripheral and central nervous system pathologies have been described, including Guillain-Barré syndrome and acute demyelinating encephalomyelitis (Brun et al., 2020; Mackenzie et al., 2021; Palaiodi mou et al., 2021; Toscano et al., 2020; Zuberbühler et al., 2021). Several demyelinating diseases are associated with psychotic symptoms. Likewise, demyelination is thought to play a role in the pathophysiology of schizophrenia, in which CNS white matter, composed largely of myelin, is reduced (Mighdoll et al., 2015). The effects of demyelination may be especially damaging during adolescence and early adulthood, when myelination is critical to the development of cognitive function (Xu and Li, 2011).

6.3. Olfactory dysfunction

Anosmia (complete loss of sense of smell) and hyposmia (decreased sense of smell) are widely associated with COVID-19, even in mild and minimally symptomatic cases (Lechien et al., 2020; Soler et al., 2020). Prevalence of olfactory dysfunction appears greater in COVID-19 compared to other respiratory viruses (Printza and Constantinidis, 2020) and is likely underestimated according to studies using objective chemosensory testing in anosmic/hyposmic COVID-19 patients (Moein et al., 2020; Vaira et al., 2020). The olfactory system’s direct connection to the CNS can provide a pathway for neurotropic agents (Machado and Gutierrez, 2020) and olfactory dysfunction is associated with both neurodegenerative diseases and schizophrenia (Doty, 2017; Moberg, 1999). Importantly, the spontaneous improvement of anosmia and hyposmia in upwards of 80–90% of COVID-19 patients suggests that the virus damages olfactory epithelium, not olfactory neurons (which do not express ACE2) (Machado and Gutierrez, 2020; Parente-Arias et al., 2021; Sayin and Yazici, 2020; Soler et al., 2020; Yan et al., 2020). However, olfactory dysfunction in COVID-19 may still be a harbinger of neuroinflammation. It has been suggested that olfactory ensheathing glial cells found in the olfactory nerve and bulb (Barnett, 2004) could serve as an intermediary between ACE2-expressing olfactory epithelial cells and olfactory neurons, inciting a local immune response (Moen et al., 2020). Because olfactory bulb microglia are in a constitutively primed state (Doty, 2017), their activation could trigger a cytokine cascade and more widespread neuroinflammation (Majde, 2010).

6.4. Systemic inflammatory response

The ability of COVID-19 to generate a massive systemic inflammatory response known as a cytokine storm is arguably its most destructive feature. This immune response results in multiorgan damage and, in many cases, death (Ahmadpoor and Rostaing, 2020). Even in milder disease, proinflammatory cytokines appear to be upregulated (Sarzi-Puttini et al., 2020) with multiple studies showing elevations in serum IL-2, IL-6, IL-8, IL-1β, tumor necrosis factor (TNF) α, and interferon (IFN) γ (Cao, 2020; Capecci et al., 2020; Wan et al., 2020). Both infection itself and hypoxia stimulate cytokine release, which can increase BBB permeability (Mukandala et al., 2016; Pan et al., 2011). COVID-19 is also associated with complement activation (Cao, 2020) and increased CRP, erythrocyte sedimentation rate (ESR), and ferritin (Chen et al., 2020b; Liu et al., 2020a; Zhu et al., 2020), all of which indicate systemic inflammation. As discussed in Section 2, systemic inflammatory markers are elevated in schizophrenia, with the potential for a neuroinflammatory response (Müller, 2018).

6.5. Neuropsychiatric symptoms in “long-haulers”

A subset of COVID-19 patients known as “long-haulers” have reported persisting neuropsychiatric symptoms for months following acute infection. These include fatigue, “brain fog,” anxiety, depression, and psychosis (Graham et al., 2021; Huang et al., 2021a; Lopez-Leon et al., 2021). This phenomenon is estimated to affect over 80% of hospitalized patients (Graham et al., 2021) and is similar to post-viral syndromes observed in prior flu pandemics (Honigsbaum and Krishnan, 2020). Remarkably, long-term neuropsychiatric symptoms of COVID-19 appear to occur even in mildly symptomatic individuals, with an estimated 10% of all patients experiencing lasting symptoms (Huang et al., 2021b; Kingstone et al., 2020; Rubin, 2020).

While new-onset psychopathology associated with COVID-19 could be driven largely by the psychological toll of being ill, the severity and prevalence of post-viral neuropsychiatric symptoms suggest that the virus may trigger a protracted immune response (Baig, 2020). Indeed, Mazza et al. (2021) found that systemic inflammation predicted depressive symptomatology and cognitive impairment three months following acute COVID-19 infection. The risk of psychiatric sequelae also appears uniquely elevated in COVID-19, as demonstrated in a large, matched cohort study in which risk of a new psychiatric diagnosis in the six months following COVID-19 infection was greater than that following other respiratory infections (Taquet et al., 2021).
6.6. Multisystem inflammatory syndrome in children

Severe COVID-19 infection was initially thought to spare children, the majority of whom have presented with milder symptoms and less inflammatory marker elevation compared to adults (Dong et al., 2020b; Leung, 2020; Ludvigsson, 2020). However, in April of 2020 the first case of COVID-19-related Kawasaki disease, an inflammatory illness that typically affects young children, was reported in a six-month-old girl (Jones et al., 2020). Since then, more reports of atypical Kawasaki-like inflammatory syndromes in children with COVID-19 have surfaced and have been termed Multisystem Inflammatory Syndrome in Children (MIS-C) (Centers for Disease Control and Prevention, 2020). Many of these cases are associated with elevated inflammatory markers including procalceitin, ferritin, and CRP (Deza Leon et al., 2020; Liciardi et al., 2020; Ripphagen et al., 2020). Although MIS-C is not associated with the majority of childhood COVID-19 infections, the acuity of the inflammatory response in those affected is worrisome given the associations between childhood infection, inflammation, and later-onset psychosis (Blomstrom et al., 2014; Khandaker et al., 2014; Liang and Chikritzhs, 2012). A large study of children and adolescents hospitalized for COVID-19 or MIS-C also showed that 22 % had neurologic involvement, raising concern for neuroinvasion and locally incited neuroinflammation (LaRovere et al., 2021). Finally, the emergence of the highly transmissible SARS-CoV-2 B117 strain has generated growing concern that pediatric infections rates will rise, particularly as schools continue to re-open (Ratmann et al., 2021).

7. Maternal COVID-19 infection

Most current data on maternal and neonatal outcomes in COVID-19 infection are limited to third trimester findings (Ashraf et al., 2020; Islam et al., 2020; Karimi et al., 2021; Liu et al., 2020b; Wang et al., 2020a). While previous literature suggests that maternal infection in earlier trimesters confers greater risk of schizophrenia in offspring (Brown et al., 2004, 2000), the literature on maternal COVID-19 infection still highlights a number of concerning features.

7.1. Vertical transmission and neonatal infection

As with influenza, HCoVs are not strongly suspected to cross the placenta. SARS and MERS showed no evidence of vertical transmission (Di Mascio et al., 2020) and the majority of case series and studies of maternal COVID-19 infection have failed to demonstrate infection in neonates, placenta, amniotic fluid, or cord blood (Baergen and Heller, 2020; Chi et al., 2021; Edlow et al., 2020; Karimi-Zarchi et al., 2020; Khan et al., 2020; Liu et al., 2020c; Muhidin et al., 2020; Pereira et al., 2020; Schwartz, 2020; Yang et al., 2020). However, there are rare reports of SARS-CoV-2 genome detection in umbilical cord blood, placenta, vaginal mucosa, breastmilk, and amniotic fluid, supporting the possibility of vertical transmission (Fenizia et al., 2020; Halici-Ozturk et al., 2021; Penfield et al., 2020; Sukhikh et al., 2021). In most reported neonatal infections, SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) testing was not done early enough to confirm vertical transmission (Ghema et al., 2021; Savasi et al., 2020; Wang et al., 2020a; Zeng et al., 2020b), though some have highlighted the possibility of false negatives in early infection (Robaina-Castellanos, 2021). There have also been reports of RT-PCR-negative infants with elevated SARS-CoV-2 IgM, an antibody too large to cross the placenta and therefore thought to signal possible in utero infection (Bwire et al., 2021; Dong et al., 2020a; Zeng et al., 2020a). This is controversial, however, as IgM has a high false positive rate in diagnosing congenital infections (Kimberlin and Stagno, 2020).

Most documented deliveries in women with COVID-19 occurred by Cesarean section (C-section) due to the debated belief that it can reduce vertical transmission risk (American College of Obstetrics and Gynecology, 2021; Ashraf et al., 2020; Chi et al., 2021; Fenizia et al., 2020; Ghema et al., 2021; Zaigham and Andersson, 2020). However, there are multiple reports of vaginal births with no detection of neonatal infection as well (Chen et al., 2020d; Cribiu et al., 2021; Muhidin et al., 2020). While vertical transmission of SARS-CoV-2 is thought to be unlikely or at least rare (Duran et al., 2020; Edlow et al., 2020; Islam et al., 2020; Makvandi et al., 2021), infants born to COVID-19-positive mothers have been shown to have elevated IL-6, CRP, and ESR, even when they themselves test negative for the infection (Dong et al., 2020a; Yu et al., 2020; Zeng et al., 2020a). Whether these abnormalities stem from undetected neonatal infection or maternal immune activation, early biological stressors may prime neonates for an increased risk of developing psychotic illness after exposure to later stressors (Howes, 2017).

7.2. Maternal immune activation in COVID-19

The physiologic and immune changes that occur during pregnancy can result in an increased severity of viral infections, as noted during the SARS and MERS pandemics (Dashraath et al., 2020). COVID-19 infection has not appeared to be more severe in pregnant women than in the general population (Savasi et al., 2020; Islam et al., 2020; de Vasconcelos Garpar and Santos Silva, 2021). However, COVID-19-positive pregnant women still commonly present with fever and elevated CRP (Breslin et al., 2020; Muhidin et al., 2020; Pereira et al., 2020; Zaigham and Andersson, 2020). First- and third-trimester gestational periods are also characterized as proinflammatory states, which could potentiate the impact of cytokine elevations seen in even mild infections (Uc, 2020). IL-6 elevation has been repeatedly observed in COVID-19 infection (Capecci et al., 2020; Liu et al., 2020a; Shi et al., 2020), including during pregnancy (Yin et al., 2020), and serves as a marker of maternal immune activation that has been implicated in the pathogenesis of schizophrenia in offspring (Aguilar-Valles et al., 2020; Martins-Filho et al., 2020; Müller, 2018; Smith et al., 2007).

7.3. Placental pathology

While several studies have demonstrated the presence SARS-CoV-2 in placental tissue (Cribiu et al., 2021; Fenizia et al., 2020; Robaina-Castellanos, 2021), the majority of studies have had negative findings in this regard (Blasco Santana et al., 2021; Chi et al., 2021; Edlow et al., 2020; Li et al., 2020b; Mirbeyk et al., 2021). It was initially thought that placental ACE2 expression might facilitate maternal-to-fetal viral transmission through the placenta (Valdés et al., 2006; Wang et al., 2020a), but this has not been clearly validated by clinical reports. For instance, Cribiu et al. (2021) demonstrated that none of the neonates of ten COVID-19-positive women with infected placental tissue contracted the virus. While ACE2 is widely expressed in the placenta, the transmembrane serine protease 2 (TMPRSS2) that activates SARS-CoV-2 is not similarly expressed (Golden and Simmons, 2020). Furthermore, ACE2 and TMPRSS2 have very little co-localization in the placenta throughout pregnancy, which may protect against fetal infection (Edlow et al., 2020; Kotiyar, 2021). Placental infection does appear to trigger expression of genes involved in the inflammatory response, which could threaten the fetus via placental damage (Cribiu et al., 2021; Fenizia et al., 2020). In COVID-positive women without known placentitis infection, there have been numerous reports of placental abnormalities such as fetal and maternal vascular malperfusion, thrombi, and infarctions, all of which indicate oxygenation abnormalities that can adversely impact the fetus. There have also been reports of inflammatory placental pathology such as villitis and umbilical arteritis (Baergen and Heller, 2020; Edlow et al., 2020; Shanes et al., 2020).

7.4. Breastfeeding

The majority of studies on postpartum women with COVID-19 did not detect SARS-CoV-2 in subjects’ breastmilk and risk of vertical transmission from breastfeeding is generally considered low (Chi et al.,
recommendations discouraging breastfeeding in COVID-19-positive mothers (Schmid et al., 2020). However, revised guidelines encourage breastfeeding with proper viral precautions (Minouni et al., 2020; Pountoukidou et al., 2021; Schwartz, 2020).

7.5. Other considerations

Clinical guidelines surrounding delivery and postnatal care in confirmed and suspected maternal COVID-19 cases have employed an abundance of caution to avoid infecting neonates. However, from a neurodevelopmental standpoint this approach may have unintended consequences. Many of these guidelines create delivery conditions likely to increase maternal and neonatal stress (Maynard et al., 2001). Many COVID-19-positive women underwent C-sections (Zaigham and Andersson, 2020), which may affect white matter development and functional connectivity, as well as negatively impact offspring’s immune system and cognitive function (Deoni et al., 2019; Polidano et al., 2017). Visitors are strictly limited, often to one, meaning that mothers undergo childbirth in relative isolation (Arora et al., 2020). Perhaps most dishearteningly, babies born to COVID-19-positive mothers cannot have skin-to-skin contact after delivery (Dashraath et al., 2020; Duran et al., 2020; Pountoukidou et al., 2021), are separated from their mothers immediately following birth, and can be isolated from them for up to several weeks (Chen et al., 2020a; Schmid et al., 2020; Schwartz, 2020). This is concerning, as the number of days infants are separated from their COVID-19-positive mothers was found to be negatively correlated with infant development in several domains (Wang et al., 2020c). Even brief maternal separation is known to increase infant cortisol (Larson et al., 1991) and there is evidence for increased microglial density in response to maternal separation (Howes, 2017).

8. Limitations

COVID-19 is a new disease and our understanding of its pathogenesis is still evolving. The body of literature on the virus is limited and conducting research during a pandemic poses unique challenges that can compromise quality (Padalia et al., 2020). The emergence of new and highly contagious strains of the virus may outpace research and make it immensely through the study of pandemics and we are hopeful that future research will elucidate how this applies to COVID-19.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of Competing Interest

The authors report no declarations of interest.

References

Aguilar-Valles, A., Rodrigue, B., Matta-Camacho, E., 2020. Maternal immune activation and the development of dopaminergic neurotransmission of the offspring: relevance for schizophrenia and other psychoses. Front. Psychiatry 11, 852. https://doi.org/10.3389/fpsyt.2020.00852.
Ahmadpoor, P., Rostaing, L., 2020. Why the immune system fails to mount an adaptive immune response to a Covid-19 infection. Transpl. Int. 33 (7), 824–825. https://doi.org/10.1111/tii.13611.
Aldhadd, B.J.S., Oler, E., Armistead, B., Elsayed, N.A., Weinberger, D.R., Bernier, R., Burd, I., Kapur, R., Jacobsson, B., Wang, C., Mysorekar, I., Rajagopal, L., Adams Waldorf, K.M., 2019. The fetal origins of mental illness. Am. J. Obstet. Gynecol. 221, 549–562. https://doi.org/10.1016/j.ajog.2019.06.013.
American College of Obstetricians and Gynecologists. 2021. FAQs for Obstetrician-Gynecologists [WWW Document]. URL https://www.acog.org/clinical-information/physicians-faq/covid-19-faq-for-ob-gyn-obstetricians (Accessed 5.2.2021).
Arabi, Y.M., Harthi, A., Hussein, J., Bouchama, A., Johani, S., Hajee, A.H., Saeed, B.T., Wahbi, A., Saedy, A., AlDabagh, T., Okail, R., Sadat, M., Balkhy, H., 2015. Severe neurolologic syndrome associated with Middle East respiratory syndrome coronavirus (MERS-CoV). Infection 43, 495–501. https://doi.org/10.1007/s15010-015-0720-y.
Arora, K.S., Mauch, J.T., Gibson, K.S., 2020. Coronavirus Disease 2019 (COVID-19): A Systematic Review of Pregnancy and the Possibility of Vertical Transmission. 21, p. 123.
Baq, A.M., 2020. Neurological manifestations in COVID-19 caused by SARS-CoV-2. CNS Neurol. Ther. 26, 498–501. https://doi.org/10.1111/cns.13572.
Barnett, S.C., 2004. Olfactory ensheathing cells: unique glial cell types? J. Neurotrauma 21, 375–382. https://doi.org/10.1089/089771504320004520.
Beach, S.R., Praschan, N.C., Hogan, C., Dotson, S., Meridith, F., Konto, N., Fricchione, G.L., Smith, F.A., 2020. Delirium in COVID-19: a case series and
exploreation of potential mechanisms for central nervous system involvement. Gen. Hosp. Psychiatry 65, 47-53. https://doi.org/10.1016/j.genhosppsych.2020.05.008.
Blasco-Santana, L., Mendoza, F., Álvarez-Sánchez García, L., Bartha, J. L., Regojo-Zapata, R.M., 2021. Maternal and perinatal outcomes and placental pathologic examination of 29 SARS-CoV-2 infected patients in the third trimester of gestation. J. Obestet. Gynaecol. Res. https://doi.org/10.1111/jog.14784.
Bloomfield, C.D., Karfis, B., Gutzman, C.R., Dal, H., Magnusson, C., Dalmán, C., 2014. Hospital admission with infection during childhood and risk for psychotic illness—a population-based cohort study. Schizophr. Bull. 40, 1518-1525. https://doi.org/10.1093/schbul/sbu195.
Boku, P., 2008. Maternal infection during pregnancy and schizophrenia. J. Psychiatry Neurosci. 33, 181-185.
Boulangier-Bertolus, J., Pancaro, C., Mashour, G.A., 2018. Increasing role of maternal infection in neurodevelopmental disorders. Front. Behav. Neurosci. 12, 230. https://doi.org/10.3389/fnbeh.2018.00230.
Breslin, N., Baptiste, C., Gyamfi-Bannerman, C., Miller, R., Martinez, R., Bernstein, K., Boulanger-Bertolus, J., Pancaro, C., Mashour, G.A., 2018. Increasing role of maternal infection in neurodevelopmental disorders. Front. Behav. Neurosci. 12, 230. https://doi.org/10.3389/fnbeh.2018.00230.
Brown, A.S., 2006. Prenatal infection as a risk factor for schizophrenia. Schizophr. Bull. 32, 200–202. https://doi.org/10.1093/oxfordjournals.schbul.d01052.
Brown, A.S., Schaefer, C.A., Wyatt, R.J., Goetz, R., Begg, M.D., Gorman, J.M., Susser, E. M., 2006. Prenatal infection as a risk factor for schizophrenia. Schizophr. Bull. 32, 200–202. https://doi.org/10.1093/oxfordjournals.schbul.d01052.
Brown, A.S., 2006. Prenatal infection as a risk factor for schizophrenia. Schizophr. Bull. 32, 200–202. https://doi.org/10.1093/oxfordjournals.schbul.d01052.
Brown, A.S., 2006. Prenatal infection as a risk factor for schizophrenia. Schizophr. Bull. 32, 200–202. https://doi.org/10.1093/oxfordjournals.schbul.d01052.
Breslin, N., Baptiste, C., Gyamfi-Bannerman, C., Miller, R., Martinez, R., Bernstein, K., Boulanger-Bertolus, J., Pancaro, C., Mashour, G.A., 2018. Increasing role of maternal infection in neurodevelopmental disorders. Front. Behav. Neurosci. 12, 230. https://doi.org/10.3389/fnbeh.2018.00230.
Kannan, G., Gressitt, K.L., Yang, S., Stallings, C.R., Katsafanas, E., Schweinfurth, L.A., Howes, O.D., 2017. Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. Transl. Psychiatry 7, e1024. https://doi.org/10.1038/srep40294.

Khandaker, G.M., Pearson, R.M., Zammit, S., Lewis, G., Jones, P.B., 2014. Association of human dipeptidyl peptidase 4 with psychotic disorders. J. Infect. Dis. 213, 712–719. https://doi.org/10.1093/infdis/jiu127.

Kirk, S., Peng, L., Siddique, R., Nabi, G., Naw sherwan Xue, M., Liu, J., Han, G., 2020. Impact of COVID-19 on pregnancy outcomes and the risk of maternal-to-neonatal intrapartum transmission of COVID-19 during natural birth. Infect. Control Hosp. Epidemiol. 1–3. https://doi.org/10.1017/ice.2020.573.

Kishk, A.M., Gm, zincron, B., Lewis, G., Jones, P.B., 2012. Childhood influenza and adult schizophrenia: a meta-analysis of population-based studies. Schizophr. Res. 139, 161–168. https://doi.org/10.1016/j.schres.2012.05.023.

Ko, W.H., Oh, Y., Kim, M., Jia, D.T., Balabanov, R., Ho, S.U., Batra, A., Liotta, E.M., Koralnik, I.J., 2021. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized COVID-19 ‘long haulers’. Ann. Clin. Transl. Neurol. https://doi.org/10.1002/acn3.2631.

Kolhoff, G., Agba, M., Saadati, H.M., Taherpour, N., Izadi, N., Nazari, S.S.H., 2020. Epidemiological and clinical aspects of COVID-19: a narrative review. Arch. Acad. Emerg. Med. R.

Korber, B., Fischer, W.M., Granakanar, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E.E., Bhattacharya, T., Foley, B., Hastie, K.M., Parker, M.D., Partridge, D.G., Evans, C.M., Freeman, T.M., de Silva, T.I., Angyal, A., Brown, R.L., Carrillo, L., et al., 2020. Tracking Changes in SARS-CoV-2 Spike: Evidence that 06–11 increases Infections in piglets. Cell 182 (4), 812–827.e10. https://doi.org/10.1016/j.cell.2020.06.043.

Kotlyar, A.M., 2021. Viral transmission of coronavirus disease 2019: a systematic review and meta-analysis. Syst. Rev. 22.

Kraeva, D., Matz, J., Weidinger, H., Wildenauer, A., Obermeier, M., Riedel, M., Müller, N., 2010. The association of infectious agents and schizophrenia. World J. Biol. Psychiatry 11, 739–743. https://doi.org/10.3109/15622630802365342.

Kroenke, R.A., Sommer, L.E., Steen, V.M., Dieset, I., Johnsen, E., 2019. Constructing the immune signature of schizophrenia for clinical use and research; an integrative review translating descriptives into diagnostics. Front. Psychiatry 9, 754. https://doi.org/10.3389/fbsp.2018.00753.

Kunst, J., Gagg, B.L., Poussaint, T.Y., Young, C.C., Newham, M.M., Maamari, M., Hor, C., et al., 2020. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. p. 12.

Larson, M., Gunnar, M., Hertsgaard, L., 1991. The effects of morning naps, car trips, and maternal separation on adrenocortical activity in human infants. Child Dev. 62, 362–372.

Lechien, J.R., Chiensa-Entoma, C.M., De Siati, D.R., Moroi, L., Le Bon, S.D., Rodriguez, A., Deungraer, D., Blecic, S., El Afia, F., Distinguin, L., Chekkouri, Abdou, T., Hassler, T., Dallal, J.B., Oudd, S., 2020. Lack of vertical transmission of SARS-CoV-2 in early pregnancy. Placenta 106, 25–37. https://doi.org/10.1016/j.placenta.2020.01.298.

Leung, C., 2020. Clinical characteristics of COVID-19 in children: are they similar to those of SARS? Pediatr. Pulmonol. 55, 1540–1547. https://doi.org/10.1002/ppul.24855.

Li, X., Okada, T., Koder, M., Nara, Y., Takino, N., Muramatsu, C., Ikeguchi, K., Urano, F., Ichinose, H., Metzger, D., Chambon, P., Nakano, I., Ozawa, K., Muramatsu, S., 2006. Ichinose, H., Metzger, D., Chambon, P., Nakano, I., Ozawa, K., Muramatsu, S., 2006. Ichinose, H., Metzger, D., Chambon, P., Nakano, I., Ozawa, K., Muramatsu, S., 2006. Ichinose, H., Metzger, D., Chambon, P., Nakano, I., Ozawa, K., Muramatsu, S., 2006. Ichinose, H., Metzger, D., Chambon, P., Nakano, I., Ozawa, K., Muramatsu, S., 2006. Ichinose, H., Metzger, D., Chambon, P., Nakano, I., Ozawa, K., Muramatsu, S., 2006. Ichinose, H., Metzger, D., Chambon, P., Nakano, I., Ozawa, K., Murama...
pregnancy and pandemic obstetric care: a review of current practices. Healthcare 9 (4), 467. https://doi.org/10.3390/healthcare9040467.

Pratchett, C., Constable, H., 2020. The role of reported smell and taste disorders in suspected COVID-19. Eur. Arch. Otorhinolaryngol. 277, 2625–2630. https://doi.org/10.1007/s00405-020-06069-6.

Prusse, M., 2017. The neural diathesis-stress model of schizophrenia revisited: an update on recent developments in illness strategy and neurobiological and methodological complexities. Neurosci. Biobehav. Rev. 73, 191–218. https://doi.org/10.1016/j.neubiorev.2016.12.013.

Raion, C., Reed, R., Rook, G., Chir, B., Miller, A., 2017. Immune system and central nervous system interactions. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. Wolters Kluwer, pp. 178–200.

Ratmann, O., Bhatt, S., Flaxman, S., 2021. Implications of a highly transmissible variant of SARS-CoV-2 for vaccination and allele–environment analysis with meta-analysis with the COVID-19 pandemic. Lancet Psychiatry. https://doi.org/10.1016/S2215-1386(21)00203-0.

Rubin, R., 2020. As their numbers grow, COVID-19 ‘long haulers’ stump experts. JAMA 324 (14), 1391–1393. https://doi.org/10.1001/jama.2020.7799.

Sah, P., Vülchès, N., Moghadas, S.M., Fitzpatrick, M.C., Singer, B.H., Hotz, P.J., Galvani, A.P., 2021. Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants. eClinicalMedicine 35, 100865. https://doi.org/10.1016/j.eclinm.2021.100865.

Sarzi-Puttini, P., Giorgi, V., Ardigò, L., Bardelli, N., Berger, C., Bassler, D., 2020. COVID-19 and the nervous system: insights from neuroimaging. Acta Physiol. e13473. https://doi.org/10.1111/apha.2020-0901-SA arpa.2020-0901-SA.

Sayin, I., Yazici, Z.M., 2020. Taste and smell impairment in SARS-CoV-2 recovers early. Head Neck. https://doi.org/10.1002/hed.26269.

Schwartz, D.A., 2020. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. Arch. Pathol. Lab. Med. https://doi.org/10.5858/apl.2020-0096-LT.

Selten, J.-P., Termorshuizen, F., 2017. The serological evidence for maternal influenza as a risk factor for psychosis in offspring is insufficient: critical review and meta-analysis. Schizophr. Res. 183, 2–9. https://doi.org/10.1016/j.schres.2016.11.006.

Severance, E.G., Dickerson, F.B., Viscidi, R.P., Bossis, I., Stallings, C.R., Origoni, A.E., McGuire, P., Fusar-Poli, P., Zandi, M.S., 2020. COVID-19 and pregnancy and pandemic obstetric care: a review of current practices. Healthcare 9 (6), 100865. https://doi.org/10.3390/healthcare906100865.

Shi, Y., Tan, M., Chen, X., Liu, Y., Huang, J., Ou, J., Deng, X., 2020. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China (preprint). Infectious Diseases (except HIV/AIDS). https://doi.org/10.1101/2020.03.03.20030339.

Shmakov, R.G., 2021. Vertical transmission of SARS-CoV-2 in second trimester pregnancies. Placenta 27, 200–207. https://doi.org/10.1016/j.placenta.2020.02.21832.

Wang, C., Zhuz-J., Huang, J., Hoon, L.C., 2020a. Intratranine vertical transmission of SARS-CoV-2: what we know so far: vertical transmission of SARS-CoV-2. Ultrasound Obstet. Gynecol. https://doi.org/10.1002/utg.21806.

Wang, C., Wuz, Z., Zhanh, J., Zhub, F., Yang, Y., Shen, X., 2020c. A case of 2019 novel coronavirus in a pregnant woman with preterm delivery. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa225.

Wang, S., Guo, L., Chen, L., Lui, W., Cao, Y., Zhang, J., 2020b. A case report of newborn COVID-19 infection in China. Clin. Infect. Dis. 71 (5), 853–857. https://doi.org/10.1093/cid/ciaa225.

Wang, X., Zhou, Z., Zhang, J., Zhu, F., Yang, Y., Shen, X., 2020d. A case of 2019 novel coronavirus in a pregnant woman with preterm delivery. Clin. Infect. Dis. 71 (5), 844–846. https://doi.org/10.1093/cid/ciaa225.

Wang, X., Xu, R., Volkow, N.D., 2021. Increased risk of COVID-19 infection and severity in patients with mental disorders: analysis from electronic health records in the United States. World Psychiatry 20 (1), 124–130. https://doi.org/10.1002/wps.22086.

Williams, J., Namazova-Baranova, L., Weber, M., Vural, M., Mestrovic, J., Carrasco-San, A., Brada, J., Berndt, N., Pettovello-Mantovani, M., 2020. The importance of continuing breastfeeding during COVID-19: in support to the WHO statement on breastfeeding during the pandemic. J. Pediatr. https://doi.org/10.1016/j.jpeds.2020.05.039.

World Health Organization. 2021. Coronavirus Disease (COVID-19) Dashboard [WWW Document]. World Health Organ. URL https://covid19.who.int/ (Accessed 11.4.2021).

World Health Organization. 2021. Coronavirus Disease (COVID-19) Dashboard [WWW Document]. World Health Organ. https://www.who.int/.../covid19.who.int/ (Accessed 11.4.2021).

Yang, P., Wang, X., Liu, P., Wei, C., He, B., Zheng, J., Zhao, D., 2020. Clinical characteristics and risk assessment of newborns born to mothers with COVID-19. J. Clin. Virol. 127, 104356. https://doi.org/10.1016/j.jcv.2020.104356.

Yang, D., Pycate, J., Joseph, J., Eichler, S., Garcia-Bumel, R., 1971. Transplantable cell lines. JAMA 216, 75. https://doi.org/10.1001/jama.216.4.75.
Yin, M.-Z., Zhang, L., Deng, G.-T., Han, C.-F., Shen, M.-X., Sun, H.-Y., Zeng, F.-R., Zhang, W., Chen, L., Luo, Q.-Q., Yao, D.-J., Wu, M., Yu, S.-H., Chen, H., Baud, D., Chen, X., 2020. Severe acute respiratory syndrome coronavirus 2 (sars-cov -2) infection during pregnancy in China: a retrospective cohort study. MedRxiv. https://doi.org/10.1101/2020.04.07.20053744, 2020.04.07.20053744.

Yolken, R.H., Torrey, E.F., 1995. Viruses, Schizophrenia, and Bipolar Disorder. Clin. Microbiol. Rev. 8, 131 – 145.

Yu, N., Li, W., Kang, Q., Xiong, Z., Wang, S., Lin, X., Liu, Y., Xiao, J., Liu, H., Deng, D., Chen, S., Zeng, W., Feng, L., Wu, J., 2020. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. Lancet Infect. https://doi.org/10.1016/S1473-3099(20)30176-6. S1473309920301766.

Zaigham, M., Andersson, O., 2020. Maternal and perinatal outcomes with COVID-19: a systematic review of 108 pregnancies. Acta Obstet. Gynecol. Scand. https://doi.org/10.1111/aogs.13867 aogs.13867.

Zeng, H., Xu, C., Fan, J., Tang, Y., Deng, Q., Zhang, W., Long, X., 2020a. Antibodies in infants born to mothers with COVID-19 pneumonia. JAMA 323 (18), 1848–1849. https://doi.org/10.1001/jama.2020.4861.

Zeng, L., Xia, S., Yuan, W., Yan, K., Xiao, F., Shao, J., Zhou, W., 2020b. Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. JAMA Pediatr. 174 (7), 722–725. https://doi.org/10.1001/jamapediatrics.2020.0878.

Zhu, J., Ji, P., Pang, J., Zhong, Z., Li, H., He, C., Zhang, J., Zhao, C., 2020. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. J. Med. Virol. https://doi.org/10.1002/jmv.25884.

Zuberbühler, P., Conti, M.E., León-Cejas, L., Maximiliano-González, F., Bonardo, P., Miquelini, A., Halfon, J., Martinez, J., Gutiérrez, M.V., Reisin, R., 2021. Guillain-Barre syndrome associated to COVID-19 infection: a review of published case reports. Rev. Neurol. 72 (March (6)), 203–212. https://doi.org/10.33586/rn.7206.2020487. English, Spanish PMID: 33710610.